DarioHealth 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- DarioHealth reported 3rd quarter 2026 revenue of $5.3 million, up 6% from $5 million in the 3rd quarter of 2025 and up 3% from $5.2 million in the 2nd quarter of 2026.
- Gross margin was 59%, compared with 60% in the 3rd quarter of 2025 and 62% in the 2nd quarter of 2026; non-GAAP B2B2C gross margin remained approximately 80% for the 11th consecutive quarter.
- Operating expenses were $11.2 million, down 10% year over year; operating loss improved 15% to $8 million, net loss was $8.8 million, and non-GAAP operating loss narrowed to $5.3 million from $6 million.
- For the first 9 months of 2026, operating expenses declined 17% and operating loss improved 22% compared with the same period last year; cash, cash equivalents, and short-term deposits totaled $31.2 million as of September 30th, 2026.
- Consumer revenue grew approximately 48% year over year and represented 53% of total revenue, compared with 38% a year ago.
- DarioHealth ended the quarter with approximately $13.1 million in contracted and late-stage annual recurring revenue, approximately 40% of which comes from health plan ASO agreements; more than 80% of contracted and late-stage recurring revenue is multi-condition.
- Channel partners accounted for about 75% of new accounts, and the company signed a New Jersey health plan representing about 1.5 million covered lives through Amwell; this was its 3rd state health plan signed through Amwell in the past 12 months.
- DarioHealth said DarioIQ is deployed across the organization and is one of several contributors to an approximately 10% year-over-year reduction in operating expenses.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2026 Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 12th, 2026. I would now like to turn the conference over to Zoe Harrison, VP Accounting and Corporate Development at DarioHealth.
Zoe, please go ahead. Thank you, operator, and good morning, everyone.
Thank you for joining us today for a discussion of DarioHealth's third quarter of 2026 financial results. Leading the call today will be Erez Raphael, Chief Executive Officer of DarioHealth. He'll be followed by John Palumbo, Chairman of the Board, Lara Dodo, our Chief Operating Officer, and Chen Franco-Yehuda, our Chief Financial Officer. An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Thursday, November 12th, 2026. This morning, we issued a press release announcing our financial results for the third quarter of 2026. A copy of the release can be found on the Investor Relations page of DarioHealth website.
I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws.
For example, the company is using forward-looking statements when it discusses expected revenue growth and contribution from signed accounts, the timing and extent of revenue recognition under existing customer agreements, the company's revenue outlook and financial performance expectations, its path to profitability and positive cash flow, the continued reduction in operating expenses and losses, its expansion of channel partnerships and distribution, expected revenue and scaling from partner-led opportunities, expected onboarding, implementation, and enrollment of large enterprise accounts, expected conversion of contracted annual recurring revenue into recognized revenue, expected expansion into care delivery, claims-based, and outcomes-based models, expected benefits from care delivery partnerships, expected growth in recurring revenue and operating leverage, expected advantages and future impact of DarioIQ and proprietary data assets, expected improvements in member engagement, retention, and outcome, the anticipated benefits of artificial intelligence across the company's commercial operations and internal operations, including expected cost savings, productivity improvements, and potential incremental revenue opportunities, the anticipated expansion of existing customer relationships into additional chronic conditions, the expected timing and contribution of new product offerings, the company's ability to increase revenue per customer through its multi-condition strategy, the expected benefits of provider-backed clinical care, the expected timing of revenue acceleration and of activation under health plan ASO agreements, beliefs regarding the convergence of consumer and payer-funded healthcare and the replatforming of chronic care management, the expected delivery of GLP-1 and other therapies within payer programs and marketplaces, the expected contribution of women and men's health programs, and beliefs regarding competitive positioning and market opportunity.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filings. Company's results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including, without limitation, the company's annual report on Form 10-K, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. With that, I will hand it over to Erez Raphael, Chief Executive Officer of DarioHealth.
Good morning, everyone, and thank you for joining us. Before we get into the quarter, I want to start with a leadership change I am very excited about. We recently announced that John Palumbo has become Chairman of our Board. John joined our Board in April of 2026, and since then, he has worked closely with our management team week after week on our commercial strategy, execution, and on where this market is going. On his first call as Chairman, John will share the Board's view on the market and Dario's position in it. In the second quarter of 2026, we described how Dario compounds across four drivers, each acting on a different part of the economics: account depth, distribution efficiency, AI leverage, and value chain participation. Let me give you a quick update on each one of them.
Account depth means more revenue from the customers we already won. Healthcare purchasers want fewer vendors and one integrated platform across conditions, and that is how we build Dario. More than 80% of our contracted and late-stage recurring revenue is now multi-condition. Every additional condition has the potential to generate two to five times more revenue in the same account, through the same implementation and the same relationship. Vendors managing multi-conditions on our platform achieve better outcomes than those managing one. Better clinical results and more revenue from the same client are a rare alignment in this industry. Distribution efficiency means more accounts faster for less. Our channel partners continue to open large populations for us, including our third state health plan, this one in New Jersey, through Amwell this quarter, without proportional increase in our sales organization.
AI leverage means more revenue per member at a lower cost to serve. We are fully vertically integrated from our own FDA-cleared devices to more than 13 billion proprietary data points, to DarioIQ, the AI engine that leverages our proprietary data and technology infrastructure. Every new member deepens the dataset, and every advance in AI raises the value of the data we own. That advantage compounds. This quarter, DarioIQ moved from individual engagement program to an integrated system that predicts which members are about to disengage and act before they do. Lara will share more about those results. Value chain participation means access to more of the healthcare dollar. During the second quarter of 2026, we said this fourth driver was just beginning. Since then, the market has moved even faster than we expected toward payers funding the therapy itself and not only the digital engagement program around it.
John will speak to that in a moment. We believe that this quarter shows the model is working, with revenue up 6% year-over-year, existing customers expanding into additional conditions, and a new state health plan signed through our channel. Lara and Ken will take you through the details. We continue to expect revenue to accelerate at the end of 2026 into 2027, driven by the conversion of contracted and late-stage annual recurring revenue. At the same time, something bigger is happening in our market. For years, the industry treated consumer health and payer-funded chronic care as two different businesses. We believe that they are becoming one, and Dario sits exactly where they meet. John Palumbo, our new Chairman, has spent his career inside the payers, providers, and health services organizations that are shaping this shift. I've asked John to walk you through this change.
John? Thank you, Erez, and good morning, everyone.
Before I go further, I want to thank Yoav Shaked for his service as Chairman. Yoav helped guide this company through a formative period, and I am glad he continues to serve on the board as we move into this next chapter. I want to start by telling you why I accepted the role. I have spent more than 40 years in healthcare, from early-stage companies to Fortune 50 enterprises. I led the provider business at AmerisourceBergen. I served as Chief Operating Officer of Allscripts, and I sit on the boards of companies across care delivery, medical device and diagnostics, conversational AI, and digital health. I have seen a lot of platforms. Very few have what Dario has built, and the market trends now underway are moving toward what Dario already does.
When I joined the board in April of 2026, I expected to help with commercial strategy. What I found working alongside Erez and this team was a company that had built, over more than a decade, the capabilities the market is now moving toward, and a strong team with a culture focused on execution, consumer experience, and trusted outcomes. I am confident in this leadership team, the company's capabilities, and the direction it is going. Let me explain what I mean by where the market is going. For a decade, consumer-paid health and payer-paid chronic care were separate markets, served by separate companies with separate economics. The consumer companies won the consumer's choice. Point solutions won a place in health plans' benefit. Almost no one did both. That wall is coming down, and I see four forces pulling it down at the same time.
First, consumers now choose their own front door. Consumers are increasingly using digital tools, including AI-enabled services, to access health information and navigate care options before engaging with healthcare providers. At home, people have easy access to self-diagnose and self-care. Easy access has never been more essential in health and care management due to our growing shortage of caregivers. Second, pharma is going direct to consumers. Manufacturers now sell branded GLP-1 health and weight therapies straight to consumers. Third, payers are redefining how they engage the members and redesigning benefit plans. Several of the largest insurers are launching plan designs with fixed upfront costs instead of deductibles, and those plans need proven programs to attract, navigate, and retain members, and to optimize care resources. Fourth, payers are bringing consumer choice inside the benefit.
We see this directly, with one of the largest national insurers has publicly repositioned itself as a consumer health company. Across our health plan relationships, we are in active discussions about extending from behavioral digital programming into clinical provider services, including access to FDA-approved branded GLP-1 prescription medications prescribed by licensed healthcare providers. The Dario platform has been built to support this market model convergence, that all the major players are moving toward. That last point is the one I would ask you to remember. The convergence of business-to-consumer, B2C, and business-to-business-to-consumer, B2B2C, is accelerating and bringing two large previously separate markets together. Payers are moving from buying programs that sit around a therapy to buying the therapy itself, delivered inside a managed and measured program. For Dario, that translates into a much larger share of the healthcare dollar, and we are already seeing it in our own results.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
